Drugplain

Sulfamethoxazole and Trimethoprim 800 mg/1

Sulfamethoxazole and Trimethoprim · TABLET · Pharmasource Meds, LLC

10 Recalls on Record
Plain English

Sulfamethoxazole and Trimethoprim is a tablet containing sulfamethoxazole and trimethoprim at 800 mg/1, taken oral. Manufactured by Pharmasource Meds, LLC.

Key Facts

Brand Name
Sulfamethoxazole and Trimethoprim
Generic Name
Sulfamethoxazole and Trimethoprim
NDC Code (Product)
82982-044
Manufacturer
Pharmasource Meds, LLC
Strength
800 mg/1
Dosage Form
TABLET
Route
ORAL
Marketing Status
Application #
ANDA090624
Drug Class
Sulfonamide Antimicrobial [EPC]; Dihydrofolate Reductase Inhibitor Antibacterial [EPC]
Marketing Start
02/28/2023

Recall History

10 Recalls on Record
Class II07/07/2021

Aurobindo Pharma USA Inc.

Presence of Foreign Substance- Potential of metal contamination.

TerminatedVoluntary: Firm initiated
Class II10/09/2015

Mutual Pharmaceutical Company, Inc.

Presence of foreign substance -This recall has been intiated due to the presence of a polyethylene piece on the finished product.

TerminatedVoluntary: Firm initiated
Class II03/17/2015

Akorn, Inc.

Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole.

TerminatedVoluntary: Firm initiated
Class II04/13/2022

Mckesson Medical-Surgical Inc. Corporate Office

cGMP deviations: Temperature abuse

TerminatedVoluntary: Firm initiated
Class II03/13/2017

Akorn Inc

Failed Dissolution Specifications

TerminatedVoluntary: Firm initiated
Class II08/18/2025

Amneal Pharmaceuticals, LLC

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

OngoingVoluntary: Firm initiated
Class II03/17/2015

Akorn, Inc.

Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole.

TerminatedVoluntary: Firm initiated
Class I06/02/2025

Amneal Pharmaceuticals, LLC

Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.

OngoingVoluntary: Firm initiated
Class II03/17/2015

Akorn, Inc.

Failed Dissolution Specifications: Out of specification for dissolution of sulfamethoxazole.

TerminatedVoluntary: Firm initiated
Class II09/27/2011

Shamrock Medical Solutions Group LLC

Labeling: Label Mix up; product labeled to contain Sulfamethoxazole and Trimethoprim Tablets, 400 mg/80 mg instead of Sulfamethoxazole and Trimethoprim Tablets, 800 mg/160 mg

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

pyrexia2,047 reports
rash1,780 reports
fatigue1,742 reports
dyspnoea1,640 reports
drug ineffective1,634 reports
pain1,605 reports
pruritus1,523 reports
infection1,410 reports
sinusitis1,369 reports
joint swelling1,367 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when i

Dosage & Administration

DOSAGE AND ADMINISTRATION Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children Adults The usual adult dosage in the treatment of urinary tract infections is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet or 2 sulfamethoxazole and trimethoprim tablets every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. Children The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage: Children 2 months of age or older: Weight Dose–every 12 hours lb kg Tablets 22 44 66 88 10 20 30 40 – 1 1½ 2 or 1 DS tablet For Patients with Impaired Renal Function When renal function is impaired, a reduced dosage should be employed using the following table: Creatinine Clearance (mL

Warnings

WARNINGS Embryofetal Toxicity Some epidemiologic studies suggest that exposure to sulfamethoxazole and trimethoprim during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If sulfamethoxazole and trimethoprim is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus. Hypersensitivity and Other Fatal Reactions Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sulfonamides, including sulfonamide-containing products such as sulfamethoxazole and trimethoprim, should be discontinued at the first appearance of skin rash or any sign of adverse reaction. In rare instances, a skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, and serious blood disorders (see

Contraindications

CONTRAINDICATIONS Sulfamethoxazole and trimethoprim tablets are contraindicated in patients with a known hypersensitivity to trimethoprim or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency. Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. Sulfamethoxazole and trimethoprim tablets are also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored.

Drug Interactions

Drug Interactions Potential for Sulfamethoxazole and Trimethoprim to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Caution is recommended when sulfamethoxazole and trimethoprim is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2. In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. It has been reported that sulfamethoxazole and trimethoprim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possi

Adverse Reactions

ADVERSE REACTIONS The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE WARNINGS SECTION). Hematologic Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, methemoglobinemia, eosinophilia. Allergic Reactions Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like syndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria and rash. In addition, periarteritis nodosa and systemic lupus erythematosus have been reported. Gastrointestinal Hepatitis (including cholestatic jaundice and hepatic necrosis)

Frequently Asked Questions

What is Sulfamethoxazole and Trimethoprim used for?

Sulfamethoxazole and Trimethoprim contains Sulfamethoxazole and Trimethoprim. It is a tablet taken oral. Consult your doctor for specific uses.

Is Sulfamethoxazole and Trimethoprim a controlled substance?

Sulfamethoxazole and Trimethoprim is not classified as a controlled substance by the DEA.

What is the generic name for Sulfamethoxazole and Trimethoprim?

The generic name for Sulfamethoxazole and Trimethoprim is Sulfamethoxazole and Trimethoprim. There are no other listed brand versions of Sulfamethoxazole and Trimethoprim.

What is the NDC code for Sulfamethoxazole and Trimethoprim 800 mg/1?

The NDC (National Drug Code) for Sulfamethoxazole and Trimethoprim 800 mg/1 is 82982-044, listed by Pharmasource Meds, LLC.